Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dronabinol + cannabidiol
- Development stage
- Phase 3
- Lead developer
- University of California, San Diego
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This investigation refers to the study of the cannabinoids dronabinol and cannabidiol (CBD) by the University of California, San Diego (UCSD), specifically for their acute effects on patients with bipolar disorder. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC) that acts as a partial agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2), mimicking the psychoactive and therapeutic effects of natural cannabis. Cannabidiol is a non-intoxicating cannabinoid with a complex pharmacological profile, acting as a negative allosteric modulator of CB1 and an agonist at the 5-HT1A receptor. The UCSD clinical program (NCT02432313) utilized a randomized, double-blind, placebo-controlled crossover design to evaluate how these substances influence cognitive performance and circulating endocannabinoid levels in individuals with bipolar disorder compared to healthy volunteers.
- Other names
- THC + CBDdelta-9-tetrahydrocannabinol + cannabidiolCannabis in Bipolar Disorder and Healthy Volunteers study drugs
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on dronabinol + cannabidiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dronabinol + cannabidiol.